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OBJECTIVES: Conflicting data from studies on the potential role of multidrug resistance 1 gene polymorphisms
in inflammatory bowel disease may result from the analysis of genetically and geographically distinct
populations. Here, we investigated whether multidrug resistance 1 gene polymorphisms are associated with
inflammatory bowel diseases in patients from Rio de Janeiro.
METHODS: We analyzed 123 Crohn’s disease patients and 83 ulcerative colitis patients to determine the
presence of the multidrug resistance 1 gene polymorphisms C1236T, G2677T and C3435T. In particular, the
genotype frequencies of Crohn’s disease and ulcerative colitis patients were analyzed. Genotype-phenotype
associations with major clinical characteristics were established, and estimated risks were calculated for the
mutations.
RESULTS: No significant difference was observed in the genotype frequencies of the multidrug resistance 1
G2677T/A and C3435T polymorphisms between Crohn’s disease and ulcerative colitis patients. In contrast, the
C1236T polymorphism was significantly more common in Crohn’s disease than in ulcerative colitis ( p= 0.047). A
significant association was also found between the multidrug resistance 1 C3435T polymorphism and the
stricturing form of Crohn’s disease (OR: 4.13; p= 0.009), whereas no association was found with penetrating
behavior (OR: 0.33; p= 0.094). In Crohn’s disease, a positive association was also found between the C3435T
polymorphism and corticosteroid resistance/refractoriness (OR: 4.14; p= 0.010). However, no significant
association was found between multidrug resistance 1 gene polymorphisms and UC subphenotypic categories.
CONCLUSION: The multidrug resistance 1 gene polymorphism C3435T is associated with the stricturing
phenotype and an inappropriate response to therapy in Crohn’s disease. This association with Crohn’s disease
may support additional pathogenic roles for the multidrug resistance 1 gene in regulating gut-microbiota
interactions and in mediating fibrosis. Understanding the effects of several drugs associated with multidrug
resistance 1 gene variants may aid in the selection of customized therapeutic regimens.
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& INTRODUCTION
Inflammatory bowel diseases (IBDs) comprise Crohn’s
disease (CD) and ulcerative colitis (UC) and are character-
ized by chronic and relapsing intestinal inflammation due to
an inappropriate immune response to the intestinal micro-
biota in a genetically predisposed individual (1). The results
obtained from genome-wide association studies have con-
tributed to the identification of distinct genetic loci
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implicated in IBD susceptibility, including pathways
involved in pro-inflammatory cell activation (2) and
autophagy (3). However, after the discovery of nucleotide-
binding oligomerization domain 2/caspase recruitment
domain-containing protein 15 (NOD2/CARD15) as the first
susceptibility gene for CD (4,5), research on IBD has
progressively shifted toward investigation of the innate
immune system and the integrity of the epithelial barrier.
Among the genes regulating innate immunity is a
member of the adenosine triphosphate-binding cassette
superfamily, ABCB1, which is also known as multidrug
resistance 1 (MDR1). MDR1 is located in an IBD suscept-
ibility locus on chromosome 7q21 (6,7) and is also involved
in epithelial integrity (8); thus, this gene has emerged as an
interesting candidate for the study of IBD pathogenesis.
Moreover, because the encoded product of the MDR1 gene,
P-glycoprotein 170 (P-gp), is highly expressed on epithelial
surfaces such as the brush borders of enterocytes (9), it has
been suggested that this transmembrane efflux pump could
participate in the function of the intestinal barrier, prevent-
ing the accumulation of toxins (10). In addition, proper P-gp
function appears to contribute to the prevention of colon
inflammation because mdr1a-knockout mice develop spon-
taneous colitis under specific pathogen-free conditions (11).
Several drugs routinely used in IBD therapy, including
corticosteroids (12,13) and immunosuppressants, such as
methotrexate (14) and cyclosporin A (15), are also substrates
of P-gp. This glycoprotein functions by transporting
molecules from the inner to the outer leaflet of the cell
membrane. High expression of the P-gp protein was
demonstrated in the peripheral blood lymphocytes and
the enterocytes of patients with CD and UC who required
surgical treatment after the failure of medical therapy. This
result prompted the investigators to hypothesize that the
lack of a response to steroids in IBD could be explained by
constitutively high MDR1 expression (16). An increased
efflux of steroids, mediated by P-gp, would then result in
decreased concentrations of cytoplasmic steroids in enter-
ocytes, reducing the drugs’ pharmacological effectiveness
(17). Nevertheless, the biological functions of these gene
variants and the question of whether they can modulate the
IBD phenotype are still unclear.
To date, studies on MDR1 gene polymorphisms and their
potential association with IBD have provided conflicting
results. Furthermore, no studies on MDR1 alleles, MDR1
genotypes and their respective frequencies have been
performed in Brazilian patients with IBD. Therefore, in
view of the conflicting data and the potential relevance of
MDR1 gene polymorphisms to determining specific IBD
behaviors, we examined the contributions of the MDR1
polymorphisms C1236T, C3435T and G2677T/A in a
southeastern Brazilian population. Additionally, we inves-
tigated the relationship between genotype and clinical
phenotype in IBD patients from Rio de Janeiro.
& MATERIALS AND METHODS
Study population
A total of 206 patients with IBD (comprising 123 patients
with CD and 83 patients with UC) were enrolled in this
study from February 2009 to January 2011. The patients
were regularly followed up at the Outpatient Unit for
Intestinal Diseases of the Disciplina de Gastreonterologia e
Endoscopia Digestiva of the Hospital Universita´rio Pedro
Ernesto, Universidade do Estado do Rio de Janeiro (HUPE/
UERJ), and of the Servic¸o de Gastreonterologia of the Hospital
Universita´rio Clementino Fraga Filho, Universidade Federal
do Rio de Janeiro (HUCCF/UFRJ). The diagnosis of IBD was
based on established diagnostic criteria, including clinical,
imaging, endoscopic and histological parameters (18).
Clinicopathological data were collected from all patients,
including gender, ethnicity, age, age at diagnosis, disease
activity, their history of surgery related to IBD, chronic steroid
use (including steroid-dependent or steroid-refractory dis-
ease) and the presence of side effects of medical treatment.
For the patients with CD, the disease location was character-
ized as the terminal ileum (L1), colon (L2), ileocolon (L3) or
upper gastrointestinal tract (L4), and the predominant disease
behavior was defined as non-stricturing, non-penetrating
(B1); stricturing (B2); or perforating (B3) according to the
Montreal classification (19). Perianal disease was considered
separately as an additional feature. CD activity assessment
was based on the Harvey-Bradshaw index (20). For the
patients with UC, disease extension was characterized based
on the Montreal classification, using modified criteria
combining ulcerative proctitis and left-sided UC (E1+E2)
and considering extensive UC separately (pancolitis; E3).
Disease activity was also assessed using the Clinical Colitis
Activity Index (21).
DNA extraction and genotyping
Peripheral blood samples were obtained from all of the
participants by venipuncture and collected in EDTA tubes.
Genomic DNA was isolated from peripheral blood leuko-
cytes by proteinase-K/sodium dodecyl sulfate digestion
and phenol-chloroform extraction, as described elsewhere
(22). The MDR1 polymorphisms most commonly described
in the literature, C1236T, G2677T and C3435T, were detected
by real-time polymerase chain reaction (PCR) followed by
direct sequencing. Specific primers were used for each
region of interest (corresponding to exons 12, 21 and 26 of
the MDR1 gene). The primers used were as follows: C1236T
sense, 59 CCTATATCCTGTGTCTGTG 39; C1236T anti-
sense, 59 CTGTGGGGTCATAGAGCCTC 39; G2677T sense,
59 AGCAGGAGTTGTTGAAATGAA 39; G2677T anti-sense,
59 AGAGCATAGTAAGCAGTAGG 39; C3435T sense, 59
CGAGCACACCTGGGCATC 39; and C3435T anti-sense, 59
GAGGCTGCCACATGCTCCCA 39. The genotype frequen-
cies of the MDR1 polymorphisms were specifically analyzed
in the study population of CD and UC patients.
Briefly, PCR was performed using the Rotor-Gene Q 2plex
HRM (Qiagen, Limburg, Netherlands) with two channels
(green and yellow). The reactions were performed in a
buffer containing 0.75 mM MgCl2, 0.2 mM dNTPs and 1.0 U
of Platinum Taq DNA polymerase (all from Invitrogen, Life
Technologies, Carlsbad, CA, USA); 20 pmol of each primer;
200 ng of genomic DNA; and sterile, ultra-pure water, to a
final volume of 50 mL. For amplification, the DNA was first
denatured for 5 minutes at 94 C˚, and 35 cycles consisting of
three steps were then performed: denaturation for 30
seconds at 92 C˚, annealing for 30 seconds at 60 C˚ (exons
12 and 21) or 58 C˚ (exon 26) and extension for 1 minute at
72 C˚. Subsequently, a final cycle of 10 minutes at 72 C˚ was
performed. The PCR products were then purified with the
Illustra GFXTM PCR DNA and Gel Band Purification Kit
according to the manufacturer’s protocol (GE Healthcare,
Buckinghamshire, UK).
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The sequencing reactions were performed using the ET
Dye Terminator Cycle Sequencing Kit (GE Healthcare)
according to the manufacturer’s protocol. The primers used
were the same as those employed in the PCR (Table 1). For
each product, eight sequencing reactions were performed:
four with sense oligonucleotides and four with anti-sense
oligonucleotides. The sequencing reactions were then
analyzed using the MegaBACE 1000 automatic sequencer
(GE Healthcare), and the sequences were analyzed using
Chromas software (http://www.technelysium.com.au/
chromas.html, accessed on March 19th, 2011) (Figure 1).
Statistical analyses
Tests for Hardy-Weinberg equilibrium were performed
using Genepop software (Genepop web version 3.1). The 5%
significance level for one degree of freedom is 3.84, and
because the qui-square value was less than this, the null
hypothesis that the population was in Hardy-Weinberg
equilibrium was not rejected.
For all other data evaluation, we used SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). The distribution of individual
characteristics was evaluated by simple descriptive statistics.
Differences among the distributions of selected variables
were evaluated using the chi-square test for categorical data.
All tests were two-tailed, and p-values of less than 0.05 were
considered statistically significant. Genotype-phenotype
associations were assessed using odds ratios (ORs) calculated
for the minor allele at each single-nucleotide polymorphism
(SNP). Multiple logistic regression models were also used to
explore the effect of genotype on the phenotypic variables,
with phenotype status as the dependent variable.
Ethical considerations
This study was approved by the Ethical Committees of
the University Hospital Pedro Ernesto, Universidade do
Table 1 - MDR1 C1236T, G2677T/A and C3435T genotypes
and allele frequencies.
Polymorphism CHz HTz RHz n
Allele
frequency x2 p-value
C T
C1236T C:C C:T T:T
Observed 90 89 27 206 0.65 0.35 0.45 0.50
Expected 88 93 25
G2677T/A G:G G:T/A T/A:T/A
Observed 81 105 20 206 0.65 0.35 2.83 0.09
Expected 87 94 25
C3435T C:C C:T T:T
Observed 92 83 31 206 0.65 0.35 2.80 0.09
Expected 87 94 25
CHz, common homozygote; HTz, heterozygote; RHz, rare homozygote.
Figure 1 - Electropherogram 1236. The wild-type sequence agggCc (left) and the polymorphism in which cytosine is exchanged for
thymine (agggTc) (right) (A). Electropherogram showing a polymorphism (C1236T) with overlapping cytosine and thymine curves,
indicating a heterozygous individual (B).
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Estado do Rio de Janeiro, and of the University Hospital
Clementino Fraga Filho, Universidade Federal do Rio de
Janeiro. Informed consent was obtained from all subjects.
The study protocol was in accordance with the ethical
principles for medical research involving human subjects
described in the Declaration of Helsinki.
& RESULTS
The CD group consisted of 49 men and 74 women with a
mean age of 39.8 years (range: 11–80 years). In total, 51 were
classified as white, whereas 72 were classified as non-white.
The mean duration of CD was 8.8 years (range: 0.5–41
years). The UC group consisted of 40 men and 43 women
with a mean age of 45.6 years (range: 21–73 years). Of these
individuals, 31 were classified as white, and 52 were
classified as as non-white. The mean duration of UC was
7.5 years (range: 0.2–27 years).
The distributions of the selected MDR1 gene polymorph-
isms (C1236T, G2677T/A and C3435T) are shown in Table 1
and demonstrate that the respective allele frequencies were
in Hardy-Weinberg equilibrium in the study population.
Subsequently, we investigated the distribution of each
polymorphic genotype in the CD and UC patient groups
(Table 2). The MDR1 G2677T/A and C3435T genotypes
were similar between CD and UC patients (p = 0.477 and
p= 0.712, respectively). However, the homozygous C1236T
genotype was significantly more prevalent among CD
patients compared with UC patients (p= 0.047).
The association of the different polymorphic genotypes
with the phenotypic characteristics of CD and UC was also
investigated. Tables 3, 4 and 5 show the genotype
frequencies of the SNPs in different subgroups of patients
with CD. A significant positive association was found
between the MDR1 homozygous C3435T polymorphism
and the stricturing form of CD (p= 0.009). Interestingly, a
tendency toward a negative association with the penetrating
form of the disease was identified for the same SNP
(p= 0.094). Among the 35 patients who had stricturing
Table 2 - Analysis of MDR1 gene polymorphisms for the
differential diagnosis of inflammatory bowel disease.
MDR1 SNP CHz HTz RHz p-value
C1236T C:C C:T T:T
CD n = 123) 50 51 22 0.047
UC (n = 83) 40 38 5
G2677T/A G:G G:T/A T/A:T/A
CD n = 123) 50 59 14 0.477
UC (n = 83) 31 46 6
C3435T C:C C:T T:T
CD n = 123) 52 52 19 0.712
UC (n = 83) 40 31 12
MDR1, multidrug resistance protein 1; SNP, single-nucleotide
polymorphism; CD, Crohn’s disease; UC, ulcerative colitis; CHz, common
homozygous; HTz, heterozygous; RHz, rare homozygous. The data were
analyzed using the Pearson chi-square test.
Table 3 - Genotype-phenotype associations of the MDR1 SNP C1236T in patients with Crohn’s disease.
MDR1 SNP C1236T CHz HTz OR p-value RHz OR p-value
Gender
Male (n = 49, 39.8%) 20 19 0.89 0.777 10 1.25 0.665
Female (n = 74, 60.2%) 30 32 12
Ethnicity
White (n = 51, 41.5%) 20 22 1.14 0.749 9 1.04 0.942
Non-white (n = 72, 58.5%) 30 29 13
Age at diagnosis
,40 (A1) (n = 62, 50.4%) 24 31 1.68 0.197 7 0.51 0.201
$40 (A2) (n = 61, 49.6%) 26 20 15
Disease location
Terminal ileum (L1) (n = 22, 17.9%) 10 11 1.10 0.846 1 0.19 0.093
Colon (L2) (n = 58, 47.1%) 23 21 0.82 0.625 14 2.05 0.168
Ileocolon (L3) (n = 38, 30.9%) 14 18 1.40 0.431 6 0.96 0.949
Upper GI (L4) (n = 5, 4.1%) 3 1 0.31 0.298 1 0.75 0.804
Disease behavior
NS/NP (B1) (n = 44, 35.8%) 17 19 1.15 0.732 8 1.11 0.846
Stricturing (B2) (n = 35, 28.4%) 15 14 0.88 0.777 6 0.88 0.814
Penetrating (B3) (n = 44, 35.8%) 18 18 0.97 0.941 8 1.02 0.976
Disease activity
Moderate/severe (n = 24, 19.5%) 8 12 1.62 0.342 4 1.17 0.819
Mild/remission (n = 99, 80.5%) 42 39 18
Surgery due to CD
Yes (n = 45, 36.6%) 23 14 0.44 0.053 8 0.67 0.447
No (n = 78, 63.4%) 27 37 14
Perianal disease
Yes (n = 37, 30.1%) 17 15 0.81 0.620 5 0.57 0.338
No (n = 86, 69.9%) 33 36 17
Chronic steroid use
Yes (n = 33, 26.8%) 10 15 1.67 0.273 8 2.29 0.139
No (n = 90, 73.2%) 40 36 14
Side effects of medication
Yes (n = 39, 31.7%) 15 18 1.27 0.570 6 0.88 0.814
No (n = 84, 68.3%) 35 33 16
CHz, common homozygote (C:C); HTz, heterozygote (C:T); RHz, rare homozygote (T:T); NS/NP, non-stricturing, non-penetrating; OR, odds ratio. All
comparisons were performed in relation to the CHz group.
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disease, 11 had the homozygous C3435T polymorphism,
whereas among the 44 patients with penetrating disease,
only three presented this genotype. Furthermore, the
homozygous C3435T polymorphism was associated with
chronic steroid use (steroid-dependent/refractory) (p=
0.010) (Table 5). A significant association with disease
behavior was also found between the MDR1 heterozygous
G2677T/A polymorphism and the non-stricturing, non-
penetrating form of CD (p= 0.033; Table 4). In contrast, no
significant associations were found between the MDR1
C1236T polymorphism and specific CD subphenotypes
(Table 3). Furthermore, no significant association was found
between the MDR1 gene polymorphisms and UC subphe-
notypic categories (Supplementary Tables S1, S2 and S3).
& DISCUSSION
In this study, we present information on the genotype
frequencies of the MDR1 C1236T, G2677T/A and C3435T
polymorphisms in patients with CD or UC as well as
potential determination of the phenotypic features of IBD, in
a southeastern Brazilian population from Rio de Janeiro. In
particular, we found that the C1236T polymorphism was
significantly more common in CD patients than in UC
patients. Regarding CD phenotypes, a significant associa-
tion was detected between the MDR1 C3435T polymorph-
ism and the stricturing form of the disease. In addition, a
positive association between the C3435T polymorphism and
the chronic use of steroids was identified in CD patients. We
also found positive and negative trends regarding specific
phenotypes and both heterozygous and homozygous poly-
morphisms, suggesting that MDR1 gene variants may
determine both susceptibility to and protection against CD.
Various MDR1 gene polymorphisms have been reported
thus far, and the C3435T polymorphism has been the most
well studied in IBD. Similar to the results of the current
study, associations between MDR1 gene polymorphisms
have been reported in refractory CD and, to a lesser extent,
in UC in a Slovenian population (23). In another study
performed in a large cohort in the United States, investiga-
tors observed a significant association between CD and a
missense polymorphism in exon 21 (G2677T/C; Ala893Ser/
Thr), which was thought to be related to altered transporter
and/or gene expression activity (24). In a case-control study
in Spain, a significant association between the MDR1
C3435T polymorphism and CD was characterized, in
addition to the identification of the CD susceptibility
haplotype 2677T/C3435 (25). Moreover, in an Italian study,
investigators found a significant association between the
C3435T SNP and the ileocolonic localization of CD, whereas
the same polymorphism appeared to be negatively asso-
ciated with a positive family history and arthritis in CD
patients (26). In a large case-control cohort study in the
United Kingdom, investigators associated the MDR1 SNPs
C3435T and G2677T/A with an increased risk of developing
UC, including an influence on disease behavior (27). In
Table 4 - Genotype-phenotype associations of the MDR1 SNP G2677T/A in patients with Crohn’s disease.
MDR1 SNP G2677T/A CHz HTz OR p-value RHz OR p-value
Gender
Male (n = 49, 39.8%) 17 26 1.53 0.284 6 1.46 0.541
Female (n = 74, 60.2%) 33 33 8
Ethnicity
White (n = 51, 41.5%) 19 26 1.29 0.521 6 1.22 0.742
Non-white (n = 72, 58.5%) 31 33 8
Age at diagnosis
,40 (A1) (n = 62, 50.4%) 24 31 1.20 0.636 7 1.08 0.894
$40 (A2) (n = 61, 49.6%) 26 28 7
Disease location
Terminal ileum (L1) (n = 22, 17.9%) 10 10 0.82 0.682 2 0.67 0.628
Colon (L2) (n = 58, 47.1%) 27 26 0.67 0.301 5 0.47 0.226
Ileocolon (L3) (n = 38, 30.9%) 11 21 1.96 0.120 6 2.66 0.118
Upper GI (L4) (n = 5, 4.1%) 2 2 0.84 0.865 1 1.85 0.623
Disease behavior
NS/NP (B1) (n = 44, 35.8%) 13 27 2.40 0.033* 4 1.14 0.847
Stricturing (B2) (n = 35, 28.4%) 16 13 0.60 0.240 6 1.59 0.449
Penetrating (B3) (n = 44, 35.8%) 21 19 0.66 0.290 4 0.55 0.362
Disease activity
Moderate/severe (n = 24, 19.5%) 8 12 1.34 0.559 4 2.10 0.286
Mild/remission (n = 99, 80.5%) 42 47 10
Surgery due to CD
Yes (n = 45, 36.6%) 23 17 0.48 0.063 5 0.65 0.493
No (n = 78, 63.4%) 27 42 9
Perianal disease
Yes (n = 37, 30.1%) 15 17 0.94 0.892 5 1.30 0.683
No (n = 86, 69.9%) 35 42 9
Chronic steroid use
Yes (n = 33, 26.8%) 12 14 0.99 0.973 7 3.17 0.060
No (n = 90, 73.2%) 38 45 7
Side effects of medication
Yes (n = 39, 31.7%) 17 20 1.00 0.991 2 0.32 0.153
No (n = 84, 68.3%) 33 39 12
CHz, common homozygous (G:G); HTz, heterozygous (G:T/A); RHz, rare homozygous (T/A:T/A); NS/NP, non-stricturing, non-penetrating; OR, odds ratio. All
comparisons were performed in relation to the CHz group.
*Indicates a significa.
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addition, in contrast to the results of the current study, case-
control studies in European cohorts of patients from
Germany (28) and Scotland (29) also suggested a potential
association between the MDR1 SNP C3435T and UC.
Nevertheless, in another Italian study, the investigated
polymorphisms in the MDR1 gene had no significant role in
disease susceptibility or the response to medical therapy in
IBD (30).
The discrepancies among these studies may be attributed
to not only different study designs, sample sizes and
selection of controls but also the distinct patient popula-
tions. In fact, meta-analyses have been performed to attempt
to overcome the heterogeneity of studies involving MDR1
SNPs. Of note, certain studies have revealed that the allele
frequencies of the three main variants differ considerably
among distinct populations. A significant association of the
3435T allele with UC was confirmed in a meta-analysis (27),
and in another study, the 3435T allele and the 3435TT
genotype were demonstrated to be significantly associated
with UC, but not with CD (31). Differences in the C3435T
SNP allele frequency have also been detected, with an
increased frequency of the C allele (wild type) in African
populations compared with Caucasian and Asian popula-
tions (32). In an Asiatic study, investigators found distinct
haplotype profiles and linkage disequilibrium at the MDR1
gene locus in all three ethnic groups enrolled in the study
(33). In a recent study that was also performed in Rio de
Janeiro, Brazil, matching the recruitment area and ethnicity
of our IBD patients, 278 healthy individuals were analyzed
regarding the genotype and allele frequencies of MDR1
gene polymorphisms. The investigators found a peculiar
variant distribution, with significant differences between
C1236C and C3435T and also between C1236C and C3435C,
which differed from the results obtained for several other
ethnic groups (34). In this context, it must be emphasized
that data from potential source populations, such as
Europeans or Africans, cannot be deemed representative
of the Brazilian genotype and allele frequencies due to the
marked heterogeneity and the extensive admixture of the
Brazilian population (35,36). Taken together with the results
of our study, these observations highlight the critical
importance of analyzing MDR1 gene polymorphisms in
Brazilians, and particularly in Brazilian IBD patients.
Potential genotype-phenotype associations related to the
MDR1 gene have been investigated, with contradictory
results. In the present study, we report positive associations
between the C3435T polymorphism and both the chronic
use of steroids and disease activity in CD patients. Similar to
our results, an association between MDR1 variants and
corticosteroid dependence was also reported in children
with CD in Canadian tertiary centers (37). In a British study
on IBD, the 2677T allele was increased in UC cases, and the
TT genotype was strongly associated with disease severity
and the use of steroids in UC (27). In contrast, in a large
Table 5 - Genotype-phenotype associations of the MDR1 SNP C3435T in patients with Crohn’s disease.
MDR1 SNP C3435T CHz HTz OR p-value RHz OR p-value
Gender
Male (n = 49, 39.8%) 22 18 0.72 0.420 9 1.23 0.703
Female (n = 74, 60.2%) 30 34 10
Ethnicity
White (n = 51, 41.5%) 22 21 0.92 0.842 8 0.99 0.988
Non-white (n = 72, 58.5%) 30 31 11
Age at diagnosis
,40 (A1) (n = 62, 50.4%) 25 27 1.17 0.695 10 1.20 0.734
$40 (A2) (n = 61, 49.6%) 27 25 9
Disease location
Terminal ileum (L1) (n = 22, 17.9%) 8 10 1.31 0.604 4 1.47 0.572
Colon (L2) (n = 58, 47.1%) 25 25 1.00 1.000 8 0.79 0.655
Ileocolon (L3) (n = 38, 30.9%) 16 16 1.00 1.000 6 1.04 0.948
Upper GI (L4) (n = 5, 4.1%) 3 1 0.32 0.307 1 0.91 0.934
Disease behavior
NS/NP (B1) (n = 44, 35.8%) 20 19 0.92 0.839 5 0.57 0.343
Stricturing (B2) (n = 35, 28.4%) 13 11 0.80 0.641 11 4.13 0.009*
Penetrating (B3) (n = 44, 35.8%) 19 22 1.27 0.547 3 0.33 0.094
Disease activity
Moderate/severe (n = 24, 19.5%) 7 11 1.72 0.299 6 2.97 0.080
Mild/remission (n = 99, 80.5%) 45 41 13
Surgery due to CD
Yes (n = 45, 36.6%) 20 20 1.00 1.000 5 0.57 0.342
No (n = 78, 63.4%) 32 32 14
Perianal disease
Yes (n = 37, 30.1%) 17 16 0.92 0.833 4 0.55 0.341
No (n = 86, 69.9%) 35 36 15
Chronic steroid use
Yes (n = 33, 26.8%) 11 12 1.12 0.813 10 4.14 0.010*
No (n = 90, 73.2%) 41 40 9
Side effects of medication
Yes (n = 39, 31.7%) 13 22 2.20 0.062 4 0.80 0.730
No (n = 84, 68.3%) 39 30 15
CHz, common homozygous (C:C); HTz, heterozygous (C:T); RHz, rare homozygous (T:T); NS/NP, non-stricturing, non-penetrating; OR, odds ratio. All
comparisons were performed in relation to the CHz group.
*Indicates a significant difference, p,0.05.
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cohort of IBD patients using steroids, both the C3435T and
the G2677T/A polymorphisms were evaluated, but no
significant differences were found within subgroups or
among subgroups. Additionally, MDR1 genotypes were not
found to influence the response to therapy (30). In another
study, the expression and function of MDR1 in intraepithe-
lial, lamina propria and peripheral blood lymphocytes were
decreased in UC patients compared with CD patients and
healthy controls (38). In accordance with this finding, the
tissue expression of a number of detoxification genes and
ABC transporters, including MDR1, was shown to be
markedly downregulated in UC patients, supporting the
notion that a defective mucosal detoxification system could
predispose a patient to intestinal inflammation (39). Indeed,
the effects of corticosteroids and other medications used in
IBD on MDR1 expression have not been fully established,
and the question of whether the difference in P-gp
expression reflects a primary defect or occurs secondary to
therapy, influencing the response to treatment, remains to
be clarified.
The stricturing form of CD, also known as the fibroste-
notic form of CD, has been previously associated with
NOD2 variants and small bowel involvement in patients
with CD (40). However, another study demonstrated that
the fibrostenotic phenotype of CD was significantly asso-
ciated with NOD2 gene variants and also with a high titer of
antibodies against oligomannan, OmpC, I2 and Cbir,
regardless of disease location (41). These results support
the notion that altered innate immunity may synergize with
a loss of tolerance to microbial antigens and with the
adaptive immune response, thus favoring a specific CD
phenotype. In contrast to studies reported thus far on MDR1
gene polymorphisms in IBD, another novel genotype-
phenotype association found in our study was the sig-
nificant positive association between the C3435T SNP and
the stricturing form of CD. Although the mechanism by
which an MDR1 SNP can determine a specific phenotype
has yet to be determined, certain evidence indicates that
MDR1 participates in a complex biological network with
multiple physiologically relevant mediators and pathways,
including pro-inflammatory cytokines (42), endotoxin-
induced inflammation (43), transcription factors such as
NF-kB (44,45) and cyclooxygenases (46), which can mod-
ulate MDR1 expression and activity at different levels.
Hence, these intricate mechanisms reinforce a key role for P-
gp in drug bioavailability and epithelial homeostasis in the
context of inflammation and infection. However, the
contribution of the MDR1 gene to the response to medica-
tions and possibly to IBD susceptibility or phenotypes,
including the stricturing form of CD, needs further
clarification.
In conclusion, the results of this study indicate that the
rare homozygous MDR1 gene polymorphism C3435T is
associated not only with the stricturing phenotype but also
with an inappropriate response to therapy in a population
of CD patients from Rio de Janeiro. The relationship with
the CD phenotype supports the existence of additional roles
for MDR1 in specific mechanisms underlying CD pathogen-
esis, such as the control of gut-microbiota interactions
and the regulation of fibrosis. Furthermore, understanding
the effects of several drugs associated with these MDR1
variants may aid in the selection of customized therapeutic
regimens.
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